Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.
about
Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.
P2860
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@ast
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@en
type
label
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@ast
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@en
prefLabel
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@ast
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@en
P2093
P2860
P50
P1433
P1476
Phase II study of alemtuzumab- ...... short- and long-term outcomes.
@en
P2093
Adam Petrich
Alfred Rademaker
Bing Bing Weitner
Jessica K Altman
Leo Gordon
LoAnn C Peterson
Olga Frankfurt
Steven T Rosen
P2860
P304
P356
10.3109/10428194.2014.910654
P577
2014-06-17T00:00:00Z